{"name":"Aura Biosciences","slug":"aura-bio","ticker":"AURA","exchange":"NASDAQ","domain":"aurabiosciences.com","description":"Aura Biosciences is a clinical-stage biopharmaceutical company focused on developing novel, targeted therapies for the treatment of cancer and eye diseases. The company's lead product candidate, AU-011, is an investigational oncolytic virus therapy for the treatment of uveal melanoma. Aura Biosciences is also developing AU-007, a novel, targeted therapy for the treatment of ocular melanoma. The company has a strong pipeline of product candidates in development, with a focus on oncology and ophthalmology.","hq":"Cambridge, MA","founded":2010,"employees":"~75","ceo":"Supinda Bunyavanich","sector":"Oncology / Ophthalmology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"2.3B","metrics":{"revenue":8000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":73302000,"netIncome":-86919000,"cash":182503000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-27","type":"regulatory","headline":"Aura Biosciences Announces FDA Clearance of Investigational New Drug (IND) Application for AU-011","summary":"Aura Biosciences announced that the FDA has cleared the IND application for AU-011, an oncolytic virus therapy for the treatment of uveal melanoma.","drugName":"AU-011","sentiment":"positive"},{"date":"2023-11-14","type":"earnings","headline":"Aura Biosciences Reports Third Quarter 2023 Financial Results","summary":"Aura Biosciences reported its third quarter 2023 financial results, with a net loss of $13.4 million.","drugName":"","sentiment":"neutral"},{"date":"2023-08-23","type":"deal","headline":"Aura Biosciences Announces Collaboration with the National Cancer Institute","summary":"Aura Biosciences announced a collaboration with the National Cancer Institute to develop new oncolytic virus therapies for the treatment of cancer.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPZEFJblJjNWs5WnJXSEg0OTIySUJ4MWNoZHhaMG1VVHJQYVFWSjg2Z1RnUG5yQkNEb0FsZTlMZk9MbHhSUnZQV05Ea1Y2UmNUNHZsQU5Ub2hYRW1ZZEpnQ2twRkNZcDBnSnhrSW1yUng0M3dzSjZNZWZYMmlPaW5nWmhQVzMtTm9yWThz?oc=5","date":"2026-04-06","type":"pipeline","source":"qz.com","summary":"Is Aura Biosciences (AURA) Stock Outpacing Its Medical Peers This Year? - qz.com","headline":"Is Aura Biosciences (AURA) Stock Outpacing Its Medical Peers This Year?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNYzBlNFpfWERqUkVqLXZ4bWNKRjVzVVJVdHNJcnhnelo3VmhiS3N1Q3NpRUxXVVU0ek5OTkNoUFZ5enJXZklLUmI0X2xncDNQQTRrdWpFd1dPaFlDM181ZUpTeFVqOTNXM1NoekZGOE5LNXpSY2dnRkpBb0ZhN190dGUzRXlhOGR3OVhqWGgzcDlzQQ?oc=5","date":"2026-04-03","type":"pipeline","source":"openpr.com","summary":"Non Muscle Invasive Bladder Cancer Pipeline 2026: Key - openpr.com","headline":"Non Muscle Invasive Bladder Cancer Pipeline 2026: Key","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOWXFHNnRRT0lvY1h4MFVhcVZQcUpkNlQ5RGhNRmpScC00UHAyOWdHY2lzUGNIb3JGTFFWMWZ5VklMX1V0U013NGYzSDF5VU4weDVuUlVGWjVpeGtwTXluYWoxcFJkVFdzUURJNnI5b2hkNnF2WFJPX0s0aXF5TkdidmZRSExCbG9kZVpFaWpYQ0pudXlBRXBtUjF4Y3c4dG0tUTJtczNURkxHR1k?oc=5","date":"2026-03-30","type":"trial","source":"Stock Titan","summary":"Bel-sar pipeline data and cash risks in Aura Biosciences (NASDAQ: AURA) 10-K - Stock Titan","headline":"Bel-sar pipeline data and cash risks in Aura Biosciences (NASDAQ: AURA) 10-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwAFBVV95cUxPZTJqS3ppNzU5QUI3UG1CR0xIbHJ2dlJ5OFZFX0lLSjBTUUxyd1RvS2VveGg0eVE2WW9HazlYZW1sS1dqT3VlNzlxYTcyUUJTQl9jNS1RNGpHTGVaWk13RXhsdnlucWNhYjR2RWl3SU94UFJJeGRMcDlEUlZZRUlvZ2k3bHRuYnowZUV1dUNldFUtMU1GRThpSGlGNEs1cW5LbW5ZTXpINnA1RDNDOHZ1dlh6dFQwemxwTlNWMUFEdW4?oc=5","date":"2026-03-30","type":"trial","source":"Stock Titan","summary":"Aura says eye melanoma Phase 3 enrollment now points to 2027 data - Stock Titan","headline":"Aura says eye melanoma Phase 3 enrollment now points to 2027 data","sentiment":"neutral"},{"date":"2026-03-30","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-30","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gJBVV95cUxPdWpfRE9DNFBKQTFKRXZxU19sY0tFVnM0NGFfVjRTdkxSSDY5OW9fRzZEMjhMWEE2Vkp2S1dha3RjZU1xTVBhcENZbjE2aHRMTW5iU0tydFRKSUREWHBHRUwzWWxVTGQxRjAza1BJaktUTFNtaUE4allvLU14WU0ybWZSMm9zOXVEVnNWY1Y4ckFRajlUendLZU1LSUZFbTZ6VTRpN2ZNYkUzRHFLdlZWakZ2bjZiX18xRVIzYjNRNld5QmQ2cEdqYWswdHJCVzk3Y0s5YS1DYVZwbVlGb1NvMmpvUjNQamhhaEx1SGlGeXdyRUN0SlhvbkJjYkF2dTd4bTktWFZOalQtRTJiTVVOampJZmVNOEV2eG1MV1pXWEpYRlduMWpZSnFnVTVHSWE2TjV4YVhCN2JIX1Z1dkFTZVpqblA5endudkRoeHRDdTdzZw?oc=5","date":"2026-03-25","type":"pipeline","source":"Barchart","summary":"Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ Pharma Companies Progress Novel Therapies Toward Market Entry, Finds DelveInsight | CG Oncology, Janssen, Tyra Biosciences, UroGen Pharma - B","headline":"Non Muscle Invasive Bladder Cancer Pipeline Expands as 20+ Pharma Companies Progress Novel Therapies Toward Market Entry","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0gFBVV95cUxObGZIVDIyVUUwckhpaEFTbXpKR2dsUzN1Sjh2SkpqSHVuX2VLRDFOX1E0THhaVzBaS3Y5eHpkc0ZjQk5vTXgwSTJjaEpBZ3Vrc3dQZjdZYVBqNTRGdWFfMkpNYnRrOE1Bdi1tczZEaUVGc1hzbGlwbW44NTdCeldHMm00RjJtNkkyajZiQUY3TzJMN00tZXNMNTA1YTJGX1huV19MVFNtWEJja0drd21FRWNnWlBCU0xTWXNKeVhmTDhNcUQ2aTZMcy1Qcmw0M3dxZHc?oc=5","date":"2026-02-25","type":"pipeline","source":"globenewswire.com","summary":"Aura Biosciences to Participate in Upcoming Investor Conferences - globenewswire.com","headline":"Aura Biosciences to Participate in Upcoming Investor Conferences","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxQNUZ5YlVPT2hRcTFxWEhOMjZ3WUczaU1KTHNZU3pBUlRJNXU4T3FfdEE3SE00c2JYNWpvODVFY1VXUi1NRTNpLTZCdUVNMVB0VXhQcjZFQTZMck1CTXpGdmhjdGN2RTBiMFdsTlBiS3hwSWctZE05bERJWXJqR1pBZHczeHRQdmUyRUpWQWlCNC1zZ3J0SlF5US0yaE9BWXc?oc=5","date":"2026-01-26","type":"pipeline","source":"BioXconomy","summary":"Biotech companies name new finance executives - BioXconomy","headline":"Biotech companies name new finance executives","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNcEJ4dmVQdlRZVEs1UE5zbkdBaUZ2TW14X0dFajlXVDBNeXVPa3VTV3o5QjJtcF83d3cwWXZIQ3dtTjVqeFlsMWdHUHp0N0lpd25YQkgwVFl5WlV0d1RrZldYRDBPdHg1OERHVXlHWDhUTXp5aVBVbXlNN0JNN3NvaFQteUs1TnlBN0ZwZ0VncWVkZw?oc=5","date":"2026-01-22","type":"pipeline","source":"pharmaphorum","summary":"Changing Faces: Board appointments, November and December 2025 - pharmaphorum","headline":"Changing Faces: Board appointments, November and December 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixAFBVV95cUxPcW90X20tenBLZTVTa2RKR0drNFNtWnp5RHViZGtGMnpBazYzLW5xWm1aT2MxOWVkRlA2MURyS2s5VmNuV1cxRGE3M3hIXzViMjIweUlvcWx3WVZRSkVZWThXcFdVLU9NWTRwb042NDV5UUNhUXR0dWVhSTZ4S1NiS3d6NkN2T01tSXpyc3R3bmxmdUJWWERlYlJsRUttWEYzbVFmZGNCWTRndGRuNmdsVU80cUc5QlhqNTdpc20zX2gxd2cy?oc=5","date":"2026-01-12","type":"pipeline","source":"Business Wire","summary":"Obsidian Therapeutics Appoints Julie Feder as Chief Financial Officer - Business Wire","headline":"Obsidian Therapeutics Appoints Julie Feder as Chief Financial Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxPd1hLVnJDZV9wVVczQjhJRnpIeFEyOE4tb1JWUGdRNWllMFdELThrc0RiVzNmSm1JS014Ui10SS1CYzJQT3lhVUZxem5SOXVQWFpacndScXY2V2tveFRRVjEyX3VrY3RQOTN3UDE4VXhKU21rMnhMV2VCRU82TnV5VnFnekswelgwQ2puX1Fhdks3SDdaTmdSRmtqQ2ttMjZSRllmTmNlbU5iQQ?oc=5","date":"2025-12-04","type":"pipeline","source":"PMLiVE","summary":"TRIMTECH Therapeutics appoints Alison Lawton as Chair of the Board - PMLiVE","headline":"TRIMTECH Therapeutics appoints Alison Lawton as Chair of the Board","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5wFBVV95cUxQbFhlaEtjRi1UVlNsRk9YYmFhellOOXFsY0hQSXhtdlM4Mjh0NzBiMVBXYUVKVFYtcGR2ZXdIQ0dmT040MlVDVGxwQ1hZU3FYSDVNQlB3cnFvVm1adk5KY0R6bTBmMlVWZWRmTVdublB5bHpNQXBzVkZ2VjZSZ1hPUjVqeE5OalJNOUlKWmJTby0tc3M3Qy1kYkNqQVhCRDRQVE1sbXZuU1lVMVVubmJ5R0RQSTRoT1JkdXRSaTlzV0lzRE1IenJqUU05VFhtM21RQkpyeGZySHZDYkxnWGJTcDktYzJ0RGvSAewBQVVfeXFMT0JLZDRvRHdfZm56QVZRa01rNC1GSnppMkMxRkVJakFTV3FQMGNrOFl4eUdHb01XR2JQUUlnaW5jckkxal9CSk1Dbmt3eW5veDdJSEE2azlWaEtOSDl2ZXF5MGVyZlBkYkUwUlFOMnFmcWVfMGJuVmF3MVBZd2lUcTBhM0VwcUhqYnl1VHJjenNNTF9CaElDdlJuYUpaOFpLcEtTT2lKMmdvUXc4T21GRU9XQW1EeUFfNGE3c2lKeHE4VFVwY0hxeG5HOHlJeHJXRkxlOG16N3Y0WkQySU1Ed2hUUmRoek9FUU45ajc?oc=5","date":"2025-11-26","type":"pipeline","source":"simplywall.st","summary":"Is Aura Biosciences (NASDAQ:AURA) In A Good Position To Deliver On Growth Plans? - simplywall.st","headline":"Is Aura Biosciences (NASDAQ:AURA) In A Good Position To Deliver On Growth Plans?","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-10-18","type":"pipeline","source":"simplywall.st","summary":"Have Insiders Sold Aura Biosciences Shares Recently? - simplywall.st","headline":"Have Insiders Sold Aura Biosciences Shares Recently?","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Iovance Biotherapeutics","NantKwest","Oncternal Therapeutics"],"therapeuticFocus":["Oncology","Ophthalmology"],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":73302000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-86919000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":182503000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}